We caught up with Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) to discuss the results of the phase 2B study of roflumilast cream in adults with chronic plaque psoriasis (ClinicalTrials.gov identifier: NCT03638258).
1. What are the limitations of current topical therapies for chronic plaque psoriasis? (0:06)
2. What is the mechanism of action of roflumilast and what are its advantages compared with other PDE4 inhibitors used in dermatology? (1:03)
3. Could you tell us a little about the ARQ-151 201 study and its efficacy and safety findings? (1:47)
4. Tell us more about the effect of roflumilast on patient-reported outcomes. (2:48)
5. What were the limitations of this study and what future studies are planned? (3:49)
Disclosures: Dr Gold Stein reports the following relationships – Arcutis: Investigator, Advisor; Dermavant: Investigator, Advisor; Leo Pharma: Investigator, Advisor; Ortho Derm: Investigator, Advisor; and Pfizer: Investigator, Advisor, Speaker.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the EADV 2020 Virtual Congress.
Share this Video
Related Videos In Psoriasis
Alan Menter, Dermatology Meeting News 2023: Ixekizumab treatment for patients with moderate-to-severe plaque psoriasis
Ixekizumab is a humanized monoclonal antibody currently approved in patients with moderate-to-severe plaque psoriasis. We caught up with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA) to discuss the aims, design, inclusion criteria and main findings of a post-hoc analysis conducted on trials studying the use of ixekizumab in adult and paediatric patients […]
Alan Menter, Dermatology Meeting News 2023: Clinical presentations and unmet needs of palmoplantar psoriasis
Palmoplantar psoriasis has a significant impact on patients’ quality of life and can be challenging to treat. touchIMMUNOLOGY were delighted to speak with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA), about the prevalence and clinical presentations of palmoplantar psoriasis, its impact on quality of life, and the unmet needs in its treatment. […]
Melinda Gooderham, Dermatology Meeting News 2023: Deucravacitinib efficacy by baseline characteristic in moderate to severe plaque psoriasis
Deucravacitinib is an allosteric tyrosine kinase 2 inhibitor approved for the treatment of moderate to severe plaque psoriasis, a post-hoc analysis of the phase 3 POETYK PSO-1 and PSO-2 trials investigated the efficacy of deucravacitinib by baseline characteristics in this indication. touchIMMUNOLOGY were delighted to speak with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!